Like our research colleagues across the entire global scientific community, our team here at Antibody Solutions continues to further delve into the complexities of SARS-CoV-2 and its mutations in hopes of further illuminating potential paths for additional discovery work. We presented our most recent findings during the 2021 PEGS Boston Virtual Conference & Expo.In this research, we’ve described three unique functional domain-specific antibodies to the CoV-2 spike protein. Their fine specificity is shown by sensitivity of binding to different spike protein constructs. The ability of the antibodies to impact spike protein function is shown by inhibition of AC2 Binding, furin cleavage, and Pseudovirus infectivity. The antibodies can serve as tools to dissect the mechanism of SARS-CoV-2 infectivity and as potential leads for COVID-19 therapeutics. Here’s a brief, five-minute video that hits the highlights of our research and findings:
While we were excited to present our research at PEGS, we also very much enjoyed the presentations delivered by other protein engineering and cell therapy leaders. If you attended PEGS, you can access the archived presentations here. (And since it's never too early too look ahead, be sure to mark your calendar for PEGS Europe, taking place virtually and in-person in Barcelona on November 2-4, 2021.)
For additional details about our SARS-CoV-2 research presented at PEGS, click here or the link below to download our poster. We would welcome your feedback on our research and approach, so please let us know what you think by contacting us here. And get in touch if we can be of any help with your research into vaccines and therapeutics for SARS-CoV-2 or other targets.
Author of more than 40 publications, John’s current research interests include new technologies for improving therapeutic antibody discovery, properties of next-generation antibody-like molecules, and best practices for critical reagents used in biologics development.